

ExonHit discloses the final terms of the acquisition of RedPath Integrated Pathology

- Acquisition paid for in cash and by issuance of shares
- Issuance of 2,834,412 new ExonHit shares

Paris, France – June 9, 2010 – The extraordinary shareholders' meeting of ExonHit Therapeutics convened to approve the acquisition of the US company, RedPath Integrated Pathology, will be held on first notice, on Monday, June 28, 2010 at 17:30 CET, at the Company's headquarters, 63-65 boulevard Masséna, 75013 Paris, France. If the quorum is not met, the meeting will be held, on second notice, on July 8, 2010, at 16:00 CET, at the Company's headquarters.

The notice of the meeting including the final terms of the transaction was published today, June 9, 2010 in the legal gazette (*Bulletin des Annonces Légales et Obligatoires* or BALO). It includes the agenda of the meeting, the resolutions submitted to shareholders' vote and the main conditions for attending the meeting and voting.

According to the terms of the agreement, upon approval of the transaction, ExonHit will pay upfront USD 12.5 million in cash and USD 10 million in stock at the closing of the transaction. On the basis of the euro/dollar conversion rate and of the ExonHit share price over the reference period described in the contribution agreement (i.e. May 3, 2010 – June 7, 2010) 2,834,412 new ExonHit shares will be issued, representing 7.95% of the 35,656,294 ordinary shares that will be outstanding after the closing.

All documents and information about the meeting are available to shareholders in accordance with current French regulations. In particular, the reports from the Management Board and from the appraisers (available in French only), as well as voting and proxy forms, may be found on the Company's website: <http://www.exonhit.com> (section "Investors"/"general meeting").

All shareholders are invited to participate, either by attending the shareholders' meeting and voting in person, or by mailing their vote, or by proxy. Such documents must be received by the Company no later than Friday, June 25, 2010. The participation of each shareholder to this meeting is important.

About RedPath Integrated Pathology, Inc.

ExonHit Therapeutics announced on April 26, 2010 the signature of a binding agreement for the acquisition of RedPath Integrated Pathology, Inc., a privately held US molecular diagnostic company, focused on cancer (2009 turnover: USD 5.4 million). According to the terms of this combination agreement, and upon approval of ExonHit's shareholders at an extraordinary shareholders' meeting, ExonHit will pay an upfront of USD 12.5 million in cash and USD 10 million in stock at the closing of the transaction. Starting in 2012, RedPath's current shareholders may receive subsequent additional payments of up to USD 9.5 million, depending on the achievement of sales targets. The transaction, if approved, is expected to close by mid-July 2010.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood based diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contacts

ExonHit Therapeutics

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com

Actifin

Emilie Dèbes
+33 1 56 88 11 23
edebe@actifin.fr

Nadège Morlais
+33 1 56 88 11 29
nmorlais@actifin.fr